• PA:215-790-7300 • NJ:609-941-2596

News & Media

NEWS: J&J Opposes Texas in $1 Billion Risperdal Marketing Trial

Margaret Cronin Fisk, David Voreacos, Jef Feeley

Bloomberg Business Week

2012-01-09 -

(Bloomberg) -- Johnson & Johnson, which has lost judgments of almost $660 million over the marketing of its antipsychotic drug Risperdal, began a trial today in which Texas is seeking damages of more than $1 billion.

State Attorney General Greg Abbott accused J&J of paying officials to get Risperdal on approved drug lists, marketing it for unapproved uses to children and the elderly, and lying about its effects. The case in state court in Austin was filed by a whistle-blower and joined by the state, which is seeking repayment of Medicaid payments.

Texas is asking for reimbursement of $579 million, said Tom Melsheimer, a lawyer for the whistle-blower. The amount could be tripled by jurors under state law. In addition, jurors will decide the number of violations and set a penalty of up to $10,000 apiece, if the state wins.

“It’s going to be massive,” said Patrick Burns of the advocacy group Taxpayers Against Fraud. “They’ll lose in Texas, and then they’re going to face litigation from stockholders for failing to settle this.”

The result may be a record false-claims verdict, Burns said by phone from Washington.

A jury weighing only the claim that the company downplayed the drug’s risks awarded Louisiana $257.7 million in 2010. A judge in South Carolina last year ordered J&J to pay $327 million over Risperdal sold in the state.

J&J and its Janssen unit, which sold Risperdal, deny any wrongdoing.

Ethics Commitment

“We are committed to ethical business practices, and have policies in place to ensure that our products are only promoted for their FDA-approved indication,” Teresa Mueller, a J&J spokeswoman, said in an e-mail. The company will fight the allegations, she said.

When questions are raised about adherence to the company’s marketing and promotion policies, “we act quickly to investigate the situation and take appropriate disciplinary action,” she said.

The Texas case goes to trial two weeks after J&J agreed to a $1 billion civil settlement with the U.S. government and some states over Risperdal sales practices, people familiar with the matter said. Texas won’t participate in the federal settlement, one of the people said. Mueller declined to comment on “rumor or speculation” about a settlement.

The company reached a tentative agreement with federal prosecutors to plead guilty to a misdemeanor criminal charge related to Risperdal marketing, J&J, based in New Brunswick, New Jersey, said in an August regulatory filing.

$400 Million More

The company is discussing a payment of about $400 million more to resolve that part of the investigation, according to one of the people familiar with the civil-suit accord.

J&J, the world’s largest health products company, and its Janssen unit have also been sued over marketing practices by Alaska, Arkansas, Louisiana, Montana, New Mexico, Pennsylvania and Utah. The Arkansas case is set for trial in March.

A suit filed by West Virginia was dropped after an appeals court set aside a nonjury trial judgment against the company. J&J won dismissal of the Pennsylvania case.

That decision and the jury’s verdict against the company in Louisiana, since enhanced to $330 million, are on appeal.

The company also has about 500 claims pending alleging injuries caused by Risperdal, it said in regulatory filings in November.

Risperdal Revenue

Risperdal, once J&J’s best-selling drug, generated worldwide sales of $24.2 billion from 2003 to 2010, peaking at $4.5 billion in 2007. After that, J&J lost patent protection and sales declined.

Risperdal profit was 97 percent of its sales, or $28.9 billion, from 1994 to 2010, Judge Roger L. Couch of South Carolina Circuit Court in Spartanburg said in his June 3 decision on damages, citing trial testimony.

Risperdal is in a class of drugs, known as atypical, or second-generation, antipsychotics. They include Eli Lilly & Co.’s Zyprexa and AstraZeneca Plc’s Seroquel. The drugs have been linked to weight gain and a risk of diabetes.

Lilly, AstraZeneca and two other J&J competitors making these drugs have paid a total of $2.66 billion to resolve government marketing claims, including allegations that the companies pushed the drugs for unapproved uses.

Indianapolis-based Lilly paid more than $1.7 billion to resolve state and federal investigations over Zyprexa. AstraZeneca, based in London, paid almost $590 million. Pfizer paid $301 million for its drug Geodon.

Texas Whistle-Blower

The Texas suit was filed by a whistle-blower, Allen Jones, an ex-investigator for the Pennsylvania Office of Inspector General.

Jones probed allegations that the chief pharmacist for the state’s mental health office had received payments from pharmaceutical companies. He sued Texas in 2004, his last year in the Pennsylvania job.

Jones determined in his probe that Janssen had “engaged in a fraudulent scheme that included payments to at least one Texas state official” to ensure that Risperdal was included as a preferred drug in the state’s Texas Medication Algorithm Project, known as TMAP, he said in court papers.

“Janssen had made payments to Texas and other state officials to facilitate the exportation of TMAP to other states, including Pennsylvania,” Jones said. He sued under a Medicaid- fraud law similar to the federal False Claims Act. It allows a whistle-blower to share in any settlement money or damages.

Health Officials

Texas claims that Janssen and J&J paid four state health officials $340,000 to promote Risperdal, inducing them to breach their duties to the state.

“J&J sent the four leaders of TMAP around the country to promote TMAP, and, in the process, Risperdal,” David Rothman, a state expert, said in a pretrial report.

“They each had to sign consulting agreements with the defendants in which they pledged their fealty to the defendants, to the exclusion of all others, including their employer, the state of Texas,” Tommy Jacks, a lawyer for the state, said at a hearing in February.

One official, the medical director of the Department of Mental Health and Mental Retardation, at one point “was spending more than half of his time with a state employee traveling around the country” at J&J’s expense “to promote the TMAP algorithm which favored their product in other states,” Jacks said at the hearing.

No Influence

The officials weren’t influenced by any payments, John Schwartz, a defense lawyer, said at the hearing. About 90 percent of the money paid went to the state, not the individuals, and their actions were approved by their superiors, Schwartz said.

“There’s no evidence from anybody that any Texas Medicaid decision-maker did anything differently as a result of anything we said or did,” John McDonald, another J&J lawyer, said at the hearing.

Texas hasn’t removed Risperdal from its list of approved drugs for Medicaid patients or restricted its use, McDonald said.

Jacks said Texas was counting only the money kept by the individuals, and didn’t include any that was turned over to the state.

The Texas attorney general joined Jones’s suit in 2006. The state government’s decision to intervene limits J&J’s chances of winning at trial, said Burns, of Taxpayers Against Fraud.

“If the government intervenes, these suits almost never go to trial, and if they go to trial, the government always wins,” Burns said.

Texas Jury

The defendants will face a jury of Texas taxpayers hearing allegations that J&J’s actions cost them money.

“If I’m the rustler, I don’t want the cow sitting in judgment,” Burns said.

The state also claims the company marketed Risperdal for so-called off-label uses, treatment of medical conditions for which it hadn’t received regulatory approval after clinical trials. It was sold for use by children and the elderly, the state says.

The Texas claims against J&J over off-label marketing mirrors those against other makers of antipsychotics, powerful medications which are sometimes prescribed for less-serious conditions than psychosis, such as depression.

Texas alleged that Janssen began promoting prescriptions for children as soon as the drug was being sold without any approvals by the U.S. Food and Drug Administration for such use.

Children Only

“They had their sales people out calling upon doctors as early as 1994 who saw no adult patients, who saw only children,” Jacks said at the February hearing. “They trained their people to sell aggressively to promote Risperdal to children and adolescents.”

One psychiatrist in north Texas who treated only children was called by Janssen sales people 96 times, Jacks said.

There was no FDA-approved indication for any use in the child and adolescent population from December 1993 to October 2006, Texas said in its complaint.

“In October 2006, Risperdal received a very narrow indication for use in a limited population of children and adolescents (age 5-17) for irritability associated with a diagnosis of autism,” the state said.

The state also will pursue its claim that the company downplayed the risks of Risperdal, despite FDA admonishments.

Texas alleged that J&J and Janssen improperly touted Risperdal as safer than competing antipsychotics in November 2003 correspondence to doctors after the FDA told the companies to enhance warnings about the drugs. This allegation was at the heart of the Louisiana and South Carolina cases.

Jury selection in Austin started today. The trial is scheduled to last about three weeks.

The case is State of Texas ex rel. Jones v. Janssen LP, D- 1GV-04-001288, District Court, Travis County, Texas (Austin).

--Editors: Charles Carter, Fred Strasser

To contact the reporters on this story: Margaret Cronin Fisk in Detroit at; David Voreacos in Newark, New Jersey, at; Jef Feeley in Wilmington, Delaware, at

To contact the editor responsible for this story: Michael Hytha at

Related Stories

J&J Said to Agree to Pay $1 Billion in Risperdal Marketing Probe Bloomberg Business Week, January 6, 2012

J&J Pushed Risperdal for Kids Without Approval, Memo Shows Bloomberg Business Week, January 17, 2012

Top Stories

Sheller, P.C. Files Class Action on behalf of Pay-Per-View (PPV) viewers of Mayweather-Pacquiao fight

ON TV: Stephen A. Sheller appeared on "How is Pharma Faring in the Courts?" on The American Law Journal

NEWS UPDATE: Actos® Drug Case Reaches Settlement

CONSUMER ALERT: Sheller, P.C. investigating link between Testosterone products and heart attack risks

Philadelphia Risperdal Trial: Jury Awards Sheller, P.C. Plaintiff $2.5 Million

WSJ: Johnson & Johnson Loses Trial Over Risperdal and Male Breast

Sheller Risperdal Trial Jury Selection Begins

Sheller, P.C. Number One in Pennsylvania for Verdicts and Settlements 2014

SAFETY NEWS: Geodon and Similar Drugs Flagged by the FDA for Potentially Fatal Skin Reactions

FEATURED CLE: Stephen Sheller Presenter on Whistleblower Qui Tam at Montco Bench Bar Conference

IN THE NEWS: Sheller Presses J&J On Behalf of Their Risperdal Clients, Trials Continue Fall 2014

Sheller Whistleblower Team: $7.3M Astellas Pharma Off-Label Marketing and FCA Settlement

IN THE NEWS: Stephen Sheller Quoted in "Low T Drug Cases Could Be Next MDL, Mass Tort"

Sheller Whistleblower False Claims Act Settlement: Florida Pain Practice Agrees to Pay Government $750,000 
to Settle Allegations of Unperformed Procedures Billed to Medicare

SHELLER FOUNDATION NEWS: Drexel's 11th Street Health Center to Expand; Sheller Gift Supports Center's Mission

IN THE NEWS: Media coverage and video of Sheller, P.C. Risperdal lawsuit settlements; Sheller represents hundreds of boys in J&J Risperdal breast growth litigation

IN THE NEWS: Stephen Sheller Quoted in Bloomberg Business Week on Whistleblowers and the Firm's Recent J&J $2.2B Settlement

NEWS: J&J to Pay at Least $2.5 Billion to Settle Hip Lawsuits

IN THE NEWS: Researchers Backpedal From Their Own Risperdal Study

IN THE NEWS: Sheller, P.C. in the Chronicle of Higher Education "University Researchers Are Seen as Enablers in Latest Major Drug Fraud"

IN THE NEWS: Sheller, P.C. in Philadelphia Inquirer "J&J to pay $2.2B for Improper Promotion of Risperdal"

NEWS: Whistleblower Law Firm Sheller, P.C. Announces $2+ Billion Johnson & Johnson Risperdal Illegal Marketing Civil and Criminal Settlement, Largest for Single Drug in U.S. History

IN THE NEWS: The Pennsylvania Record reports that Sheller attorneys have filed an additional Risperdal case on behalf of Texas client

IN THE NEWS: Sheller Whistleblower UMass medical billing fraud case settles for 66k

NEWS: OIG Medicare/Medicaid Whistleblower Fraud Alert and WSJ story on Physician-owned distributorships (PODs) of medical devices

IN THE NEWS: Attorney Stephen Sheller "Lawyer Spars With FDA Over J&J Risperdal Court Documents"

IN THE NEWS: Stephen Sheller in Philadelphia Inquirer "FDA Slow to Ask J&J for Drug Data"

IN THE NEWS: Stephen A. Sheller, founding partner of Sheller, P.C., was quoted in the The Philadelphia Inquirer article "High Court Sides with Philadelphia Drug Firm"

NEWS: Lipitor May Increase Diabetes Risk

NEWS: FDA Investigates Two Deaths in Zyprexa Patients

IN THE NEWS: Attorney Stephen Sheller Featured Television Panelist Discussing FDA and Pharma Executives, The American Law Journal

NEWS: Dispute Flares Inside FDA Over Safety of Popular Blood-Pressure Drugs

NEWS: SuperLawyers 2013: Seven Sheller, P.C. Attorneys honored, Stephen Sheller for 10th straight year

NEWS: Study of Babies Did Not Disclose Risks, U.S. Finds; Sheller Attorneys Investigating on Behalf of Families

NEWS: NFL & Players Have Their First Day in Court

IN THE NEWS: Sheller, P.C. Settlement Featured in The Legal Intelligencer "Top 10" since 1994

NEWS: Regulator Issues Fraud Alert on Doctor-Owned Distributors

IN THE NEWS: "Justice for All" in the Temple Times newspaper: Sheller Center for Social Justice

NEWS: Sheller Family Foundation Gift Establishes Social Justice Center at Temple University Beasley School of Law

NEWS: Health Care Fraud Cases Yield $4.2 billion

NEWS: Shire agrees to settle ADHD drug inquiry

NEWS: Court says Pfizer can be sued by man who took generic drug

IN THE NEWS: Stephen Sheller quoted in "Will A Court Ruling Usher In Off-Label Promotions?"

IN THE NEWS: Stephen Sheller quoted in Philadelphia Inquirer article "Court Ruling Could Grant Latitude on Drug Claims"

IN THE NEWS: Stephen Sheller profiled in Philadelphia Life Magazine

IN THE NEWS: Sheller, P.C. appeals Summary Judgement in favor of Risperdal ghostwriters, Attorney Brian J. McCormick, Jr. quoted in Law 360/LexisNexis article

IN THE NEWS: Sheller Risperdal settlements front page of The Legal Intelligencer

NEWS: Sheller attorneys investigate reports of Allergan Lap-Band injuries and deaths

IN THE NEWS: Attorney Brian J. McCormick, Jr. quoted on blog "Risperdal schizophrenia drug makes boys grow breasts"

NEWS: Sheller Client's Mother Asks Judge in Risperdal Trial to Release J&J Report for Jurors

SPEAKER: Attorney Jamie Sheller to present hip implant litigation strategies

IN THE NEWS: Sheller Products Liability Trial in Risperdal Case Opens in Phila.

NEWS: Sheller, P.C. filing center of Bloomberg article "J&J CEO Should Be Forced to Testify Teens Lawyers Say"

NEWS: J&J Settles with Sheller, P.C. client on first day of Risperdal jury trial

IN THE NEWS: Sheller, P.C. profiled in Suburban Life magazine

NEWS: Stephen Sheller quoted by Pharma Gossip Blog on Off-Label Marketing of Drugs

SPEAKER: Attorney Jamie Sheller Featured Speaker at Annual NetDiligence Cyber Risk and Privacy Liability Forum

SPEAKER: Attorney Jamie Sheller presented at the PBI conference "How to Properly Document Settlement Agreements"

NEWS: Sheller, P.C. Attorneys Honored Again in 2012 as SuperLawyers®

IN THE NEWS: Stephen A. Sheller and Brian J. McCormick, Jr. on Insider Exclusive "Deadly Drugs: Johnson & Johnson's Risperdal®"

IN THE NEWS: Stephen A. Sheller on Insider Exclusive Documentaries

LEGAL PUBLICATIONS NEWS: Sheller, P.C. #1 settlement in Pennsylvania, 2010

IN THE NEWS: Stephen Sheller Quoted on Arkansas Risperdal $1.2B verdict in Gannett and Philadelphia Newspapers

NEWS: J&J's Marketing of Risperdal Violated Law, Arkansas Jury Rules, $1.1B Penalty

NEWS: Generic Drugs Proving Resistant to Damage Suits

NEWS: Philadelphia Trial Lawyers Ask First Judicial District to Rethink Mass Torts Rules

IN THE NEWS: Attorney Jamie Sheller Quoted in Article on Paula Abdul Slip and Fall Lawsuit

NEWS: J&J to Pay $158M in Risperdal Case; Sheller Quoted on Mass Tort Litigation

NEWS: J&J Pushed Risperdal for Kids Without Approval, Memo Shows

NEWS: J&J Opposes Texas in $1 Billion Risperdal Marketing Trial

NEWS: J&J Said to Agree to $1B in Risperdal Marketing Probe

IN THE NEWS: Attorney Stephen Sheller comments on the potential legal issues in the Penn State sexual abuse allegations

NEWS: Sheller, P.C. releases new video series, "What Is a Whistleblower Claim?"

IN THE NEWS: Sheller 'Live Stop' Class Action, Story of Sheller Client in the Philadelphia Daily News

IN THE NEWS: Attorney Jamie Sheller Quoted by Business Insurance on Data Breach Issues

NEWS: Sheller, P.C. Files Lawsuits Over Police 'Live Stop' Tactics

WHISTLEBLOWER WEBINAR: Attorney Stephen Sheller presented LexisNexis program

NEWS: Sheller, P.C. Attorneys Recognized as 2011 SuperLawyers®

IN THE NEWS: Attorney Stephen Sheller Interviewed by FOX on 'Live Stop' Traffic Enforcement Class Action

NEWS: Attorney Stephen Sheller files suit claiming Philly cops use 'live stop' statute to seize cars illegally

NEWS: Jury Finds Risperdal Manufacturer Violated Consumer Laws; Sheller Attorneys Continue to Pursue Justice for Injured Children


NEWS: Attorney Stephen Sheller Honored With First "Pioneer" Award at AAJ Conference

NEWS: Sheller Attorneys Win Class Cert. in 'Light' Tobacco, Potential Actual Damages of Billions for Consumers in Minnesota

NEWS: Jamie Sheller is Featured Presenter at DePuy Hip Implant Recall Litigation Conference, November 3, 2010

NEWS: Stephen Sheller quoted in New York Times article "Side Effects May Include Lawsuits"

IN THE COMMUNITY: Stephen Sheller throws first pitch at Philadelphia Phillies

IN THE COMMUNITY: Stephen Sheller Honored by U.S. Commanding General for Iraq for Dedication to PA National Guard

NEWS: Jamie Sheller in and Legal Intelligencer on Paxil Birth Defects Cases

NEWS: Pennsylvania Higher Education Foundation Announces Sheller Scholarships

NEWS: Sheller, P.C. attorneys honored once again as SuperLawyers®, 2010

NEWS: Shellers Sponsor Pennsylvania National Guard Exhibit at the National Liberty Museum

NEWS: $520 Million Brings Total Sheller Pharma Whistleblower Settlements to $4.2 Billion

CONSUMER ALERT: Sheller, P.C. Attorneys investigating injuries from recalled Nissan vehicles

CONSUMER ALERT: Sheller, P.C. investigating injuries reported by drivers of Toyotas, concern mounts over accidents in models not listed in recall

NEWS: Stephen Sheller quoted on front page of San Francisco Chronicle

NEWS: Stephen Sheller quoted in Legal Intelligencer story about Toyota litigation

NEWS: Jamie Sheller interviewed in The Philadelphia Inquirer about her client injured by MTD Snowthrower

NEWS UPDATE Toyota Recall: Sheller, P.C. Filing National Class Action Against Toyota

NEWS: Stephen Sheller interviewed on WHYY about Whistleblower/False Claims Act cases

NEWS: New Paxil Birth Defects Cases

NEWS UPDATE: Sheller plans filing twenty to thirty more Risperdal/ Invega cases

NEWS: Sheller, P.C. Files Lawsuits Against Manufacturers of Antipsychotic Drugs Risperdal and Invega

CONSUMER ALERT: Recalled Flu Vaccine Prompts Sheller, P.C. Investigation

NEWS: Sheller, P.C. attorney Jamie Sheller appears on special broadcast of The American Law Journal

IN THE COMMUNITY: Shellers honored at National Philanthropy Day Awards

VERDICT: Jamie Sheller represents client in $2.5 million Paxil birth defects verdict

VERDICT: Sheller, P.C. Whistleblower Case: $2.3 Billion Settlement

VERDICT: Sheller, P.C. Whistleblower Case: $1.4 Billion Settlement

CONSUMER ALERT: Is there a link between antidepressants and Autism?

Sheller, P.C. Number One in Pennsylvania for Verdicts and Settlements 2014

Links / Associations